OPEN END TURBO CALL WARRANT - AMGEN | Delayed Deutsche Boerse AG 08:24:01 21/06/2024 BST | ||
| 1.31 EUR | -1.50% |
|
| Current month | +3.10% | ||
| 1 month | -2.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 1.31 | -1.50% |
| 20/06/24 | 1.33 | +5.56% |
| 19/06/24 | 1.26 | -3.08% |
| 18/06/24 | 1.3 | +2.36% |
| 17/06/24 | 1.27 | +2.42% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 08:24 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | UBS |
| WKN | UH2HC6 |
| ISIN | DE000UH2HC62 |
| Date issued | 03/09/2021 |
| Strike | 166.1 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.55 € |
|---|---|
| Lowest since issue | 0.43 € |
| Spread | 0.1 € |
| Spread % | 7.09% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.9
USD
Average target price
316.4
USD
Spread / Average Target
+2.11%
- Stock Market
- Certificates
- Certificat
